Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Department of Internal Medicine, Adventhealth Orlando, Orlando, FL, USA.
Crit Rev Oncol Hematol. 2020 Nov;155:103091. doi: 10.1016/j.critrevonc.2020.103091. Epub 2020 Sep 1.
Fibroblast growth factor receptor (FGFR) inhibitors have shown promising results in terms of objective response rates in phase I/II trials in various malignancies that harbor FGFR genetic aberrations. The class of medications brings in the concept of 'personalized' treatment by targeting susceptible FGFR genetic alterations in some rare but dismal cancers such as cholangiocarcinoma. Despite the fact that FGFR inhibitors are well-tolerated, these drugs are associated with toxicities that are distinct from that of other small-molecule tyrosine kinase inhibitors. These toxicities can result in dose reductions, interruptions, and even drug discontinuation as reported in the clinical trials. The prevention and effective management of the FGFR inhibitor-associated toxicities will allow patients to stay on these medications without the therapy interruptions. The current work is focused on summarizing the available literature on unique FGFR inhibitor-associated toxicities with a special emphasis in managing the unique adverse events.
成纤维细胞生长因子受体（FGFR）抑制剂在具有 FGFR 基因异常的各种恶性肿瘤的 I/II 期试验中显示出令人鼓舞的客观缓解率，这表明该类药物具有良好的疗效。该类药物通过针对某些罕见但预后不良的癌症（如胆管癌）中易感的 FGFR 基因改变，引入了“个体化”治疗的概念。尽管 FGFR 抑制剂具有良好的耐受性，但这些药物与其他小分子酪氨酸激酶抑制剂的毒性不同。正如临床试验所报道的那样，这些毒性可能导致剂量减少、中断甚至停药。预防和有效管理 FGFR 抑制剂相关毒性可使患者在不中断治疗的情况下继续使用这些药物。目前的工作重点是总结关于独特的 FGFR 抑制剂相关毒性的现有文献，特别强调管理独特的不良事件。
